ZA201805205B - Combination products for the treatment of rsv - Google Patents
Combination products for the treatment of rsvInfo
- Publication number
- ZA201805205B ZA201805205B ZA2018/05205A ZA201805205A ZA201805205B ZA 201805205 B ZA201805205 B ZA 201805205B ZA 2018/05205 A ZA2018/05205 A ZA 2018/05205A ZA 201805205 A ZA201805205 A ZA 201805205A ZA 201805205 B ZA201805205 B ZA 201805205B
- Authority
- ZA
- South Africa
- Prior art keywords
- rsv
- treatment
- combination products
- products
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16154035 | 2016-02-03 | ||
| PCT/EP2017/052201 WO2017134133A1 (en) | 2016-02-03 | 2017-02-02 | Combination products for the treatment of rsv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201805205B true ZA201805205B (en) | 2020-10-28 |
Family
ID=55304886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/05205A ZA201805205B (en) | 2016-02-03 | 2018-08-02 | Combination products for the treatment of rsv |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10363253B2 (enExample) |
| EP (2) | EP3411028B1 (enExample) |
| JP (1) | JP7065030B2 (enExample) |
| KR (1) | KR20180108598A (enExample) |
| CN (2) | CN108601774B (enExample) |
| AU (2) | AU2017214246B2 (enExample) |
| BR (1) | BR112018014958A2 (enExample) |
| CA (1) | CA3006488A1 (enExample) |
| CL (3) | CL2018001808A1 (enExample) |
| EA (3) | EA202092250A1 (enExample) |
| ES (1) | ES2877808T3 (enExample) |
| IL (2) | IL259669B (enExample) |
| MX (2) | MX2020012592A (enExample) |
| MY (1) | MY197217A (enExample) |
| PH (2) | PH12020551598B1 (enExample) |
| SG (1) | SG11201806581TA (enExample) |
| UA (1) | UA124099C2 (enExample) |
| WO (1) | WO2017134133A1 (enExample) |
| ZA (1) | ZA201805205B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2957868C (en) | 2014-10-10 | 2023-02-28 | Pulmocide Limited | Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative |
| US10160772B2 (en) | 2014-12-18 | 2018-12-25 | Pulmocide Limited | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives |
| US10626126B2 (en) | 2016-04-08 | 2020-04-21 | Pulmocide Limited | Compounds |
| TW201936193A (zh) | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療ｒｓｖ |
| PH12022551042A1 (en) * | 2019-10-30 | 2023-05-29 | Janssen Sciences Ireland Unlimited Co | Synthesis of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one |
| CN114014856B (zh) * | 2021-11-26 | 2023-12-22 | 嘉兴安谛康生物科技有限公司 | 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物 |
| CN116077494A (zh) * | 2023-01-11 | 2023-05-09 | 黑龙江中医药大学 | 一种治疗呼吸道合胞病毒的药物组合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI515187B (zh) * | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| PT2988780T (pt) * | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
| CA2921294C (en) * | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| CA2957868C (en) | 2014-10-10 | 2023-02-28 | Pulmocide Limited | Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivative |
-
2017
- 2017-02-02 ES ES17702125T patent/ES2877808T3/es active Active
- 2017-02-02 KR KR1020187020776A patent/KR20180108598A/ko not_active Withdrawn
- 2017-02-02 CN CN201780009640.0A patent/CN108601774B/zh not_active Expired - Fee Related
- 2017-02-02 MX MX2020012592A patent/MX2020012592A/es unknown
- 2017-02-02 EA EA202092250A patent/EA202092250A1/ru unknown
- 2017-02-02 UA UAA201809060A patent/UA124099C2/uk unknown
- 2017-02-02 WO PCT/EP2017/052201 patent/WO2017134133A1/en not_active Ceased
- 2017-02-02 EA EA202092251A patent/EA202092251A1/ru unknown
- 2017-02-02 EA EA201891655A patent/EA037206B1/ru unknown
- 2017-02-02 EP EP17702125.0A patent/EP3411028B1/en active Active
- 2017-02-02 SG SG11201806581TA patent/SG11201806581TA/en unknown
- 2017-02-02 US US16/075,103 patent/US10363253B2/en active Active
- 2017-02-02 PH PH1/2020/551598A patent/PH12020551598B1/en unknown
- 2017-02-02 CN CN202010988991.4A patent/CN112245429A/zh active Pending
- 2017-02-02 EP EP21170919.1A patent/EP3892273A3/en not_active Withdrawn
- 2017-02-02 BR BR112018014958-6A patent/BR112018014958A2/pt not_active Application Discontinuation
- 2017-02-02 MX MX2018009422A patent/MX381654B/es unknown
- 2017-02-02 JP JP2018540796A patent/JP7065030B2/ja not_active Expired - Fee Related
- 2017-02-02 CA CA3006488A patent/CA3006488A1/en active Pending
- 2017-02-02 AU AU2017214246A patent/AU2017214246B2/en not_active Ceased
- 2017-02-02 MY MYPI2018001388A patent/MY197217A/en unknown
-
2018
- 2018-05-29 IL IL259669A patent/IL259669B/en active IP Right Grant
- 2018-06-29 CL CL2018001808A patent/CL2018001808A1/es unknown
- 2018-08-02 PH PH12018501649A patent/PH12018501649B1/en unknown
- 2018-08-02 ZA ZA2018/05205A patent/ZA201805205B/en unknown
-
2019
- 2019-05-29 CL CL2019001455A patent/CL2019001455A1/es unknown
- 2019-05-29 CL CL2019001454A patent/CL2019001454A1/es unknown
-
2020
- 2020-09-10 IL IL277281A patent/IL277281B/en active IP Right Grant
-
2022
- 2022-03-25 AU AU2022202070A patent/AU2022202070A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275482A (en) | Asketamine for the treatment of depression | |
| IL277281B (en) | Combined products for the treatment of respiratory syncytial virus | |
| SI3524255T1 (sl) | Sestavek za zdravljenje aken | |
| GB201608885D0 (en) | Treatment | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| ZA201604687B (en) | Combination product for the prevention of sexually transmitted infections | |
| ZA201806806B (en) | Method for the treatment or prevention of osteoarthritis. | |
| IL258137B1 (en) | HIV treatment measures | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| IL273835A (en) | Combined product for cancer treatment | |
| ZA201806807B (en) | Method for the treatment or prevention of osteoarthritis | |
| IL275027A (en) | Treatment of RSV with a combined product | |
| PL3151899T3 (pl) | Urządzenie do leczenia zwężeń przełyku | |
| IL252774A0 (en) | A pharmaceutical preparation for the treatment of fungus | |
| PT3340975T (pt) | Formulação para o tratamento de acne | |
| IL267059A (en) | A preparation for the treatment of osteoarthritis | |
| GB201701928D0 (en) | Compounds for the treatment of hyperglycaemia | |
| GB201617107D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment | |
| GB201609683D0 (en) | Treatment | |
| PT3524255T (pt) | Composição para o tratamento do acne | |
| GB201505183D0 (en) | Concept 52 |